Salient features and management options of macular telangiectasia type 2: a review and update

References

• Gass JD, Oyakawa RT. Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study. Arch Ophthalmol. 1982;100(5):769–780.
   PubMedGoogle Scholar
• Gass JD, Blodi BA. Idiopathic juxtafoveolar retinal telangiectasis. Ophthalmology. 1993;100(10):1536–1546.
   PubMed Web of Science ®Google Scholar
• Yannuzzi LA, Bardal AM, Freund KB, et al. Idiopathic macular telangiectasia. Arch Ophthalmol. 2006;124(4):450–460.
   PubMedGoogle Scholar
• Charbel Issa P, Gillies MC, Chew EY, et al. Macular telangiectasia type 2. Prog Retin Eye Res. 2013;34:49–77.
   PubMed Web of Science ®Google Scholar
• Klein R, Blodi BA, Meuer SM, et al. The prevalence of macular telangiectasia type 2 in the Beaver Dam eye study. Am J Ophthalmol. 2010;150(1):55–62 e2.
   PubMed Web of Science ®Google Scholar
• Aung KZ, Wickremasinghe SS, Makeyeva G, et al. The prevalence estimates of macular telangiectasia type 2: the melbourne collaborative cohort study. Retina. 2010;30(3):473–478.
   PubMed Web of Science ®Google Scholar
• Sallo FB, Leung I, Mathenge W, et al. The prevalence of type 2 idiopathic macular telangiectasia in two African populations. Ophthalmic Epidemiol. 2012;19(4):185–189.
   PubMed Web of Science ®Google Scholar
• Gillies MC, Zhu M, Chew E, et al. Familial asymptomatic macular telangiectasia type 2. Ophthalmology. 2009;116(12):2422–2429.
   PubMed Web of Science ®Google Scholar
• Clemons TE, Gillies MC, Chew EY, et al. Baseline characteristics of participants in the natural history study of macular telangiectasia (mactel) mactel project report no 2. Ophthalmic Epidemiol. 2010;17(1):66–73.
   PubMed Web of Science ®Google Scholar
• Oh KT, Park DW. Bilateral juxtafoveal telangiectasis in a family. Retina. 1999;19(3):246–247.
   PubMed Web of Science ®Google Scholar
• Hutton WL, Snyder WB, Fuller D, et al. Focal parafoveal retinal telangiectasis. Arch Ophthalmol. 1978;96(8):1362–1367.
   PubMedGoogle Scholar
• Chew EY, Murphy RP, Newsome DA, et al. Parafoveal telangiectasis and diabetic retinopathy. Arch Ophthalmol. 1986;104(1):71–75.
   PubMedGoogle Scholar
• Siddiqui N, Fekrat S. Group 2A idiopathic juxtafoveolar retinal telangiectasia in monozygotic twins. Am J Ophthalmol. 2005;139(3):568–570.
   PubMed Web of Science ®Google Scholar
• Menchini U, Virgili G, Bandello F, et al. Bilateral juxtafoveolar telangiectasis in monozygotic twins. Am J Ophthalmol. 2000;129(3):401–403.
   PubMed Web of Science ®Google Scholar
• Hannan SR, Madhusudhana KC, Rennie C, et al. Idiopathic juxtafoveolar retinal telangiectasis in monozygotic twins. Br J Ophthalmol. 2007;91(12):1729–1730.
   PubMed Web of Science ®Google Scholar
• Brue C, Tseng JJ, Barbazetto I, et al. Peculiar manifestation of macular telangiectasia type 2. Retin Cases Brief Rep. 2011;5(4):309–312.
   PubMedGoogle Scholar
• Abujamra S, Bonanomi MT, Cresta FB, et al. Idiopathic juxtafoveolar retinal telangiectasis: clinical pattern in 19 cases. Ophthalmologica. 2000;214(6):406–411.
   PubMed Web of Science ®Google Scholar
• Sallo FB, Leung I, Chung M, et al. Retinal crystals in type 2 idiopathic macular telangiectasia. Ophthalmology. 2011;118(12):2461–2467.
   PubMed Web of Science ®Google Scholar
• Moisseiev J, Lewis H, Bartov E, et al. Superficial retinal refractile deposits in juxtafoveal telangiectasis. Am J Ophthalmol. 1990;109(5):604–605.
   PubMed Web of Science ®Google Scholar
• Margalit E, Apte RS, Sadda SR. Idiopathic parafoveal telangiectasis associated with a foveal pseudovitelliform lesion. Br J Ophthalmol. 2002;86(12):1455–1456.
   PubMed Web of Science ®Google Scholar
• Albini TA, Benz MS, Coffee RE, et al. Optical coherence tomography of idiopathic juxtafoveolar telangiectasia. Ophthalmic Surg Lasers Imaging. 2006;37(2):120–128.
   PubMedGoogle Scholar
• Charbel Issa P, Helb HM, Holz FG, et al. Correlation of macular function with retinal thickness in nonproliferative type 2 idiopathic macular telangiectasia. Am J Ophthalmol. 2008;145(1):169–175.
   PubMed Web of Science ®Google Scholar
• Koizumi H, Slakter JS, Spaide RF. Full-thickness macular hole formation in idiopathic parafoveal telangiectasis. Retina. 2007;27(4):473–476.
   PubMed Web of Science ®Google Scholar
• Engelbrecht NE, Aaberg TM Jr., Sung J, et al. Neovascular membranes associated with idiopathic juxtafoveolar telangiectasis. Arch Ophthalmol. 2002;120(3):320–324.
   PubMedGoogle Scholar
• Davidorf FH, Pressman MD, Chambers RB. Juxtafoveal telangiectasis-a name change? Retina. 2004;24(3):474–478.
   PubMed Web of Science ®Google Scholar
• Jindal A, Choudhury H, Pathengay A, et al. A novel clinical sign in macular telangiectasia type 2. Ophthalmic Surg Lasers Imaging Retina. 2015;46(1):134–136.
   PubMed Web of Science ®Google Scholar
• Ablonczy Z, Crosson CE. VEGF modulation of retinal pigment epithelium resistance. Exp Eye Res. 2007;85(6):762–771.
   PubMed Web of Science ®Google Scholar
• Surguch V, Gamulescu MA, Gabel VP. Optical coherence tomography findings in idiopathic juxtafoveal retinal telangiectasis. Graefes Arch Clin Exp Ophthalmol. 2007;245(6):783–788.
   PubMed Web of Science ®Google Scholar
• Powner MB, Gillies MC, Tretiach M, et al. Perifoveal muller cell depletion in a case of macular telangiectasia type 2. Ophthalmology. 2010;117(12):2407–2416.
   PubMed Web of Science ®Google Scholar
• Gaudric A, Ducos De Lahitte G, Cohen SY, et al. Optical coherence tomography in group 2A idiopathic juxtafoveolar retinal telangiectasis. Arch Ophthalmol. 2006;124(10):1410–1419.
   PubMedGoogle Scholar
• Sallo FB, Peto T, Egan C, et al. The IS/OS junction layer in the natural history of type 2 idiopathic macular telangiectasia. Invest Ophthalmol Vis Sci. 2012;53(12):7889–7895.
   PubMed Web of Science ®Google Scholar
• Sallo FB, Peto T, Egan C, et al. “En face” OCT imaging of the IS/OS junction line in type 2 idiopathic macular telangiectasia. Invest Ophthalmol Vis Sci. 2012;53(10):6145–6152.
   PubMed Web of Science ®Google Scholar
• Barthelmes D, Gillies MC, Sutter FK. Quantitative OCT analysis of idiopathic perifoveal telangiectasia. Invest Ophthalmol Vis Sci. 2008;49(5):2156–2162.
   PubMed Web of Science ®Google Scholar
• Charbel Issa P, Berendschot TT, Staurenghi G, et al. Confocal blue reflectance imaging in type 2 idiopathic macular telangiectasia. Invest Ophthalmol Vis Sci. 2008;49(3):1172–1177.
   PubMed Web of Science ®Google Scholar
• Charbel Issa P, Finger RP, Helb HM, et al. A new diagnostic approach in patients with type 2 macular telangiectasia: confocal reflectance imaging. Acta Ophthalmol. 2008;86(4):464–465.
   PubMed Web of Science ®Google Scholar
• Bottoni F, Eandi CM, Pedenovi S, et al. Integrated clinical evaluation of type 2A idiopathic juxtafoveolar retinal telangiectasis. Retina. 2010;30(2):317–326.
   PubMed Web of Science ®Google Scholar
• Snodderly DM, Auran JD, Delori FC. The macular pigment. II. Spatial distribution in primate retinas. Invest Ophthalmol Vis Sci. 1984;25(6):674–685.
   PubMed Web of Science ®Google Scholar
• Snodderly DM, Brown PK, Delori FC, et al. The macular pigment. I. Absorbance spectra, localization, and discrimination from other yellow pigments in primate retinas. Invest Ophthalmol Vis Sci. 1984;25(6):660–673.
   PubMed Web of Science ®Google Scholar
• Shen W, Zhang J, Chung SH, et al. Submacular DL-alpha-aminoadipic acid eradicates primate photoreceptors but does not affect luteal pigment or the retinal vasculature. Invest Ophthalmol Vis Sci. 2011;52(1):119–127.
   PubMed Web of Science ®Google Scholar
• Nussbaum JJ, Pruett RC, Delori FC. Historic perspectives macular yellow pigment. The first 200 years. Retina. 1981;1(4):296–310.
   PubMedGoogle Scholar
• Whitehead AJ, Mares JA, Danis RP. Macular pigment: a review of current knowledge. Arch Ophthalmol. 2006;124(7):1038–1045.
   PubMed Web of Science ®Google Scholar
• Charbel Issa P, van der Veen RL, Stijfs A, et al. Quantification of reduced macular pigment optical density in the central retina in macular telangiectasia type 2. Exp Eye Res. 2009;89(1):25–31.
   PubMed Web of Science ®Google Scholar
• Helb HM, Issa PC, van der Veen RL, et al. Abnormal macular pigment distribution in type 2 idiopathic macular telangiectasia. Retina. 2008;28(6):808–816.
   PubMed Web of Science ®Google Scholar
• Delori FC, Dorey CK, Staurenghi G, et al. In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. Invest Ophthalmol Vis Sci. 1995;36(3):718–729.
   PubMed Web of Science ®Google Scholar
• Roorda A, Romero-Borja F, Donnelly Iii W, et al. Adaptive optics scanning laser ophthalmoscopy. Opt Express. 2002;10(9):405–412.
   PubMed Web of Science ®Google Scholar
• Ooto S, Hangai M, Takayama K, et al. High-resolution photoreceptor imaging in idiopathic macular telangiectasia type 2 using adaptive optics scanning laser ophthalmoscopy. Invest Ophthalmol Vis Sci. 2011;52(8):5541–5550.
   PubMed Web of Science ®Google Scholar
• Jacob J, Krivosic V, Paques M, et al. Cone density loss on adaptive optics in early macular telangiectasia type 2. Retina. 2016;36(3):545–551.
   PubMed Web of Science ®Google Scholar
• Huang S, Shen M, Zhu D, et al. In vivo imaging of retinal hemodynamics with OCT angiography and doppler OCT. Biomed Opt Express. 2016;7(2):663–676.
   PubMed Web of Science ®Google Scholar
• Chidambara L, Gadde SG, Yadav NK, et al. Characteristics and quantification of vascular changes in macular telangiectasia type 2 on optical coherence tomography angiography. Br J Ophthalmol. 2016. doi:10.1136/bjophthalmol-2015-307941.
   PubMedGoogle Scholar
• Spaide RF, Klancnik JM Jr., Cooney MJ, et al. Volume-rendering optical coherence tomography angiography of macular telangiectasia type 2. Ophthalmology. 2015;122(11):2261–2269.
   PubMed Web of Science ®Google Scholar
• Charbel Issa P, Helb HM, Rohrschneider K, et al. Microperimetric assessment of patients with type 2 idiopathic macular telangiectasia. Invest Ophthalmol Vis Sci. 2007;48(8):3788–3795.
   PubMed Web of Science ®Google Scholar
• Charbel Issa P, Troeger E, Finger R, et al. Structure-function correlation of the human central retina. PLoS One. 2010;5(9):e12864.
   PubMed Web of Science ®Google Scholar
• Clemons TE, Gillies MC, Chew EY, et al. The national eye institute visual function questionnaire in the macular telangiectasia (mactel) project. Invest Ophthalmol Vis Sci. 2008;49(10):4340–4346.
   PubMed Web of Science ®Google Scholar
• Maruko I, Iida T, Sekiryu T, et al. Early morphological changes and functional abnormalities in group 2A idiopathic juxtafoveolar retinal telangiectasis using spectral domain optical coherence tomography and microperimetry. Br J Ophthalmol. 2008;92(11):1488–1491.
   PubMed Web of Science ®Google Scholar
• Schmitz-Valckenberg S, Fan K, Nugent A, et al. Correlation of functional impairment and morphological alterations in patients with group 2A idiopathic juxtafoveal retinal telangiectasia. Arch Ophthalmol. 2008;126(3):330–335.
   PubMedGoogle Scholar
• Schmitz-Valckenberg S, Ong EE, Rubin GS, et al. Structural and functional changes over time in mactel patients. Retina. 2009;29(9):1314–1320.
   PubMed Web of Science ®Google Scholar
• Wong WT, Forooghian F, Majumdar Z, et al. Fundus autofluorescence in type 2 idiopathic macular telangiectasia: correlation with optical coherence tomography and microperimetry. Am J Ophthalmol. 2009;148(4):573–583.
   PubMed Web of Science ®Google Scholar
• Bringmann A, Iandiev I, Pannicke T, et al. Cellular signaling and factors involved in muller cell gliosis: neuroprotective and detrimental effects. Prog Retin Eye Res. 2009;28(6):423–451.
   PubMed Web of Science ®Google Scholar
• Bringmann A, Pannicke T, Grosche J, et al. Muller cells in the healthy and diseased retina. Prog Retin Eye Res. 2006;25(4):397–424.
   PubMed Web of Science ®Google Scholar
• Gass JD. Muller cell cone, an overlooked part of the anatomy of the fovea centralis: hypotheses concerning its role in the pathogenesis of macular hole and foveomacualr retinoschisis. Arch Ophthalmol. 1999;117(6):821–823.
   PubMedGoogle Scholar
• Chopdar A. Retinal telangiectasis in adults: fluorescein angiographic findings and treatment by argon laser. Br J Ophthalmol. 1978;62(4):243–250.
   PubMed Web of Science ®Google Scholar
• Park DW, Schatz H, McDonald HR, et al. Grid laser photocoagulation for macular edema in bilateral juxtafoveal telangiectasis. Ophthalmology. 1997;104(11):1838–1846.
   PubMed Web of Science ®Google Scholar
• Lowe MA, Akduman L, Olk RJ. Laser photocoagulation and glucose metabolism in idiopathic juxtafoveolar retinal telangiectasis. Ophthalmic Surg Lasers. 1998;29(2):126–139.
   PubMedGoogle Scholar
• Kiraly A, Nasemann JE. [idiopathic juxtafoveolar telangiectasis long-term follow-up of visual acuity]. Ophthalmologe. 1995;92(5):698–703.
   PubMedGoogle Scholar
• Friedman SM, Mames RN, Stewart MW. Subretinal hemorrhage after grid laser photocoagulation for idiopathic juxtafoveolar retinal telangiectasis. Ophthalmic Surg. 1993;24(8):551–553.
   PubMedGoogle Scholar
• De Lahitte GD, Cohen SY, Gaudric A. Lack of apparent short-term benefit of photodynamic therapy in bilateral, acquired, parafoveal telangiectasis without subretinal neovascularization. Am J Ophthalmol. 2004;138(5):892–894.
   PubMed Web of Science ®Google Scholar
• Alldredge CD, Garretson BR. Intravitreal triamcinolone for the treatment of idiopathic juxtafoveal telangiectasis. Retina. 2003;23(1):113–116.
   PubMed Web of Science ®Google Scholar
• Cakir M, Kapran Z, Basar D, et al. Optical coherence tomography evaluation of macular edema after intravitreal triamcinolone acetonide in patients with parafoveal telangiectasis. Eur J Ophthalmol. 2006;16(5):711–717.
   PubMed Web of Science ®Google Scholar
• Martinez JA. Intravitreal triamcinolone acetonide for bilateral acquired parafoveal telangiectasis. Arch Ophthalmol. 2003;121(11):1658–1659.
   PubMedGoogle Scholar
• Smithen LM, Spaide RF. Photodynamic therapy and intravitreal triamcinolone for a subretinal neovascularization in bilateral idiopathic juxtafoveal telangiectasis. Am J Ophthalmol. 2004;138(5):884–885.
   PubMed Web of Science ®Google Scholar
• Eandi CM, Ober MD, Freund KB, et al. Anecortave acetate for the treatment of idiopathic perifoveal telangiectasia: a pilot study. Retina. 2006;26(7):780–785.
   PubMed Web of Science ®Google Scholar
• Charbel Issa P, Scholl HP, Holz FG. Short-term effects of intravitreal bevacizumab in type ii idiopathic macular telangiectasia. Retin Cases Brief Rep. 2007;1(4):189–191.
   PubMedGoogle Scholar
• Charbel Issa P, Holz FG, Scholl HP. Findings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Ophthalmology. 2007;114(9):1736–1742.
   PubMed Web of Science ®Google Scholar
• Charbel Issa P, Finger RP, Holz FG, et al. Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Br J Ophthalmol. 2008;92(7):941–945.
   PubMed Web of Science ®Google Scholar
• Charbel IP, Finger RP, Kruse K, et al. Monthly ranibizumab for nonproliferative macular telangiectasia type 2: a 12-month prospective study. Am J Ophthalmol. 2011;151(5):876–86 e1.
   PubMed Web of Science ®Google Scholar
• Toy BC, Koo E, Cukras C, et al. Treatment of nonneovascular idiopathic macular telangiectasia type 2 with intravitreal ranibizumab: results of a phase II clinical trial. Retina. 2012;32(5):996–1006.
   PubMed Web of Science ®Google Scholar
• Yourey PA, Gohari S, Su JL, et al. Vascular endothelial cell growth factors promote the in vitro development of rat photoreceptor cells. J Neurosci. 2000;20(18):6781–6788.
   PubMed Web of Science ®Google Scholar
• Sigler EJ, Randolph JC, Calzada JI, et al. Pars plana vitrectomy with internal limiting membrane removal in type 2 idiopathic macular telangiectasia. Retin Cases Brief Rep. 2013;7(4):380–385.
   PubMedGoogle Scholar
• Sigler EJ, Randolph JC, Calzada JI, et al. Comparison of observation, intravitreal bevacizumab, or pars plana vitrectomy for non-proliferative type 2 idiopathic macular telangiectasia. Graefes Arch Clin Exp Ophthalmol. 2013;251(4):1097–1101.
   PubMed Web of Science ®Google Scholar
• Chew EY, Clemons TE, Peto T, et al. Ciliary neurotrophic factor for macular telangiectasia type 2: results from a phase 1 safety trial. Am J Ophthalmol. 2015;159(4):659–66 e1.
   PubMed Web of Science ®Google Scholar
• Park D, Schatz H, McDonald HR, et al. Fibrovascular tissue in bilateral juxtafoveal telangiectasis. Arch Ophthalmol. 1996;114(9):1092–1096.
   PubMedGoogle Scholar
• Lee BL. Bilateral subretinal neovascular membrane in idiopathic juxtafoveolar telangiectasis. Retina. 1996;16(4):344–346.
   PubMed Web of Science ®Google Scholar
• Watzke RC, Klein ML, Folk JC, et al. Long-term juxtafoveal retinal telangiectasia. Retina. 2005;25(6):727–735.
   PubMed Web of Science ®Google Scholar
• Potter MJ, Szabo SM, Chan EY, et al. Photodynamic therapy of a subretinal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis. Am J Ophthalmol. 2002;133(1):149–151.
   PubMed Web of Science ®Google Scholar
• Potter MJ, Szabo SM, Sarraf D, et al. Photodynamic therapy for subretinal neovascularization in type 2A idiopathic juxtafoveolar telangiectasis. Can J Ophthalmol. 2006;41(1):34–37.
   PubMed Web of Science ®Google Scholar
• Shanmugam MP, Agarwal M. RPE atrophy following photodynamic therapy in type 2A idiopathic parafoveal telangiectasis. Indian J Ophthalmol. 2005;53(1):61–63.
   PubMedGoogle Scholar
• Rishi P, Shroff D, Rishi E. Combined photodynamic therapy and intravitreal ranibizumab as primary treatment for subretinal neovascular membrane (SRNVM) associated with type 2 idiopathic macular telangiectasia. Graefes Arch Clin Exp Ophthalmol. 2008;246(4):619–621.
   PubMed Web of Science ®Google Scholar
• Ruys J, De Laey JJ, Vanderhaeghen Y, et al. Intravitreal bevacizumab (Avastin) for the treatment of bilateral acquired juxtafoveal retinal telangiectasis associated with choroidal neovascular membrane. Eye (Lond). 2007;21(11):1433–1434.
   PubMed Web of Science ®Google Scholar
• Shukla D, Singh J, Kolluru CM, et al. Transpupillary thermotherapy for subfoveal neovascularization secondary to group 2A idiopathic juxtafoveolar telangiectasis. Am J Ophthalmol. 2004;138(1):147–149.
   PubMed Web of Science ®Google Scholar
• Maia OO Jr., Bonanomi MT, Takahashi WY, et al. Intravitreal bevacizumab for foveal detachment in idiopathic perifoveal telangiectasia. Am J Ophthalmol. 2007;144(2):296–299.
   PubMed Web of Science ®Google Scholar
• Jorge R, Costa RA, Calucci D, et al. Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Graefes Arch Clin Exp Ophthalmol. 2007;245(7):1045–1048.
   PubMed Web of Science ®Google Scholar
• Shanmugam MP, Mythri HM, Shetty NS. Intravitreal bevacizumab for parafoveal telangiectasia-associated choroidal neovascular membrane. Indian J Ophthalmol. 2007;55(6):490–491.
   PubMedGoogle Scholar
• Mandal S, Venkatesh P, Abbas Z, et al. Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia. Graefes Arch Clin Exp Ophthalmol. 2007;245(12):1825–1829.
   PubMed Web of Science ®Google Scholar
• Berger AS, McCuen BW 2nd, Brown GC, et al. Surgical removal of subfoveal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Retina. 1997;17(2):94–98.
   PubMed Web of Science ®Google Scholar